Şevin Turcan

German Cancer Research Center — Germany

Medicine · Health Sciences

27h-index10.4kcitations71works0.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(39), Epigenetics and DNA Methylation(25), Histone Deacetylase Inhibitors Research(11), Protein Degradation and Inhibitors(7), Hearing, Cochlea, Tinnitus, Genetics(6)

Publications70 total

KMT2A is a prerequisite of malignant transformation during IDH-mutant gliomagenesis
Neuro-Oncology·2026
GSK3 acts as a switch for transcriptional programs in a model of low-grade gliomagenesis
Acta Neuropathologica Communications·2025Open Access
Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models
Journal of Biological Chemistry·2025· 1 citedOpen Access
A microdeletion event at 19q13.43 in IDH-mutant astrocytomas is strongly correlated with MYC overexpression
Acta Neuropathologica Communications·2024Open Access
Catalytically distinct IDH1 mutants tune phenotype severity in tumor models
2024Open Access
SIRT2 inhibition as the Achilles’ heel of ATRX-deficient gliomas
Neuro-Oncology·2023Open Access
CSIG-18. WNT SIGNALING MODULATES TUMORIGENIC FEATURES AND CELLULAR IDENTITY IN A MODEL OF LOW-GRADE GLIOMAGENESIS
Neuro-Oncology·2023Open Access
EPCO-33. H3K4 METHYLATION IS A PREREQUISITE OF CELL FATE CHANGE DURING IDH-MUTANT GLIOMAGENESIS
Neuro-Oncology·2023Open Access
Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas
Cell Reports Medicine·2023· 30 citedOpen Access
Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip
Advanced Healthcare Materials·2023· 14 citedOpen Access
Important Requirements for Desorption/Ionization Mass Spectrometric Measurements of Temozolomide-Induced 2′-Deoxyguanosine Methylations in DNA
Cancers·2023· 2 citedOpen Access
CIC reduces xCT/SLC7A11 expression and glutamate release in glioma
Acta Neuropathologica Communications·2023· 22 citedOpen Access
TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing
Neuro-Oncology·2022· 32 citedOpen Access
Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas
International Journal of Cancer·2022· 10 citedOpen Access
<i>MEOX2</i> homeobox gene promotes growth of malignant gliomas
Neuro-Oncology·2022· 24 citedOpen Access
Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells
Neoplasia·2022· 16 citedOpen Access
Epigenetic Drugs and Their Immune Modulating Potential in Cancers
Biomedicines·2022· 19 citedOpen Access
Approaching Sites of Action of Temozolomide for Pharmacological and Clinical Studies in Glioblastoma
Biomedicines·2021· 11 citedOpen Access
TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing
2021· 2 citedOpen Access
CBIO-20. HIGH LEVELS OF TERT CONFER SENSITIVITY TO THE DNA HYPOMETHYLATING AGENT DECITABINE (DAC) IN GLIOMAS
Neuro-Oncology·2021Open Access
page 1 of 4Next →

Frequent Co-authors

Timothy A. Chan(15), Christel Herold‐Mende(8), Wolfgang Wick(7), Julián Taranda(7), Douglas E. Vetter(7), Xueyuan Sun(7), Ashwin Narayanan(7), Logan A. Walsh(6), Agnès Viale(6), Engin Demirdizen(6), Luc G.T. Morris(5), Jason T. Huse(5), Jong‐Whi Park(5), Armida W. M. Fabius(4), Ingo K. Mellinghoff(4), Timothy A. Chan(4), Cameron Brennan(4), Felix Sahm(4), Ruslan Al‐Ali(4), Kasthuri Kannan(4)